



Melinta Therapeutics
44 Whippany Road, Suite 280
Morristown, NJ 07960

To whom it may concern at the Office of the Vermont Attorney General:

Pursuant to 18 V.S.A. § 4637 ("Notice of Introduction of New High-Cost Prescription Drugs"), this email serves to notify your agency that Melinta Therapeutics, LLC ("Melinta") is introducing a new drug in the commercial market. Please see the information below that is required for the initial notice:

Name of Manufacturer	Name of the Prescription Drug	Anticipated Date of Release
Melinta Therapeutics, LLC	KIMYRSA™ (oritavancin)	July 2021

Melinta takes seriously its obligation to fully comply with all laws and regulations, including drug notification and pricing requirements, and therefore will be submitting its full drug notice to your agency with the required information in advance of the 30-day deadline.

If your agency has any comments or questions, please do not hesitate to reach out.

Regards,

Jennifer Sanfilippo
Sr. Vice President, General Counsel